Back to Search Start Over

Computational Investigation of 1, 3, 4 Oxadiazole Derivatives as Lead Inhibitors of VEGFR 2 in Comparison with EGFR : Density Functional Theory, Molecular Docking and Molecular Dynamics Simulation Studies

Authors :
Bilal, Muhammad Sajjad
Ejaz, Syeda Abida
Zargar, Seema
Akhtar, Naveed
Wani, Tanveer A.
Riaz, Naheed
Aborode, Adullahi Tunde
Siddique, Farhan
Altwaijry, Nojood
Alkahtani, Hamad M.
Umar, Haruna Isiyaku
Bilal, Muhammad Sajjad
Ejaz, Syeda Abida
Zargar, Seema
Akhtar, Naveed
Wani, Tanveer A.
Riaz, Naheed
Aborode, Adullahi Tunde
Siddique, Farhan
Altwaijry, Nojood
Alkahtani, Hamad M.
Umar, Haruna Isiyaku
Publication Year :
2022

Abstract

Vascular endothelial growth factor (VEGF) is an angiogenic factor involved in tumor growth and metastasis. Gremlin has been proposed as a novel therapeutic pathway for the treatment of renal inflammatory diseases, acting via VEGFR 2 receptor. To date, most FDA-approved tyrosine kinase (TK) inhibitors have been reported as dual inhibitors of EGFR and VEGFR 2. The aim of the present study was to find the potent and selective inhibitor of VEGFR 2 specifically for the treatment of renal cancer. Fourteen previously identified anti-inflammatory compounds i.e., 1, 3, 4 oxadiazoles derivatives by our own group were selected for their anti-cancer potential, targeting the tyrosine kinase (TK) domain of VEGFR2 and EGFR. A detailed virtual screening-based study was designed viz density functional theory (DFT) study to find the compounds stability and reactivity, molecular docking for estimating binding affinity, SeeSAR analysis and molecular dynamic simulations to confirm protein ligand complex stability and ADMET properties to find the pharmacokinetic profile of all compounds. The DFT results suggested that among all the derivatives, the 7g, 7j, and 7l were chemically reactive and stable derivatives. The optimized structures obtained from the DFTs were further selected for molecular docking, and the results suggested that 7g, 7j and 7l derivatives as the best inhibitors of VEGFR 2 with binding energy values -46.32, -48.89 and -45.01 kJ/mol. The Estimated inhibition constant (IC50) of hit compound 7j (0.009 mu M) and simulation studies of its complexes confirms its high potency and best inhibitor of VEGFR2. All the derivatives were also docked with EGFR, where they showed weak binding energies and poor interactions, important compound 7g, 7j and 7i exhibited binding energy of -31.01, -33.23 and -34.19 kJ/mol respectively. Furthermore, the anticancer potential of the derivatives was confirmed by cell viability (MTT) assay using breast cancer and cervical cancer cell lines. At th<br />Funding Agencies|King Saud University, Riyadh Saudi Arabia [RSP-2021/357]

Details

Database :
OAIster
Notes :
application/pdf, English
Publication Type :
Electronic Resource
Accession number :
edsoai.on1372243289
Document Type :
Electronic Resource
Full Text :
https://doi.org/10.3390.biom12111612